Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2003

View Archived Issues

SPL-7013 gel prevents SIV transmission in SIV-infected macaques

Fidarestat prevents retinal oxidative stress and overexpression of VEGF

FDA approves carvedilol for reducing risk of myocardial infarction

Novel IGF-1R inhibitors in early development at Amgen

AstraZeneca presents N-type calcium channel antagonists as potential analgesic agents

H+/K+-ATPase inhibitors and their use described by AstraZeneca researchers

Taisho describes new antibacterial erythromycins

PDE4 inhibitors described by Merck Frosst for asthma and other uses

Nonimmunosuppressive rapamycins for neurodegeneration, cancer and restenosis

New alpha7 nicotinic agonists in Pharmacia pipeline

Novel PDH activators discovered by AstraZeneca scientists

Novartis acquires majority stake in Idenix

Epix Medical selects EP-2104R for clinical development

Further analyses of Riquent phase III and phase II/III data

Recruitment completed in phase II trial of Metastat in Kaposi's sarcoma

DCF-987 constituent awarded orphan drug status for cystic fibrosis

Further analysis of Lescol LIPS results

Pharmexa applies to begin phase I trial of HER-2 Protein AutoVac product

Amylin submits additional Symlin information to Swiss authorities

IND filed for XL-784

New breast cancer gene discovered

Procyon to acquire Pharmacor

Chronic T-1032 proves beneficial in dogs with heart failure

Cardiovascular effects of MMP inhibitor Ono-4817 discussed at Japanese Circulation Society meeting

Andrographolide analogues a focus of anticancer research at Dr. Reddy's

IND filed for anti-HIV drug candidate AMD-070

ACS news: inhibitors of phosphate transport for use in patients with chronic renal disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Deals and an M&A strengthen end-of-year numbers
BioWorld
Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints
BioWorld
Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...